Belite Bio (BLTE) Common Equity (2020 - 2025)

Belite Bio's Common Equity history runs 6 years deep, the most recent figure standing at $770.5 million for Q4 2025.

• In Q4 2025, Common Equity rose 428.38% year-over-year to $770.5 million; the TTM figure through Dec 2025 stood at $770.5 million (up 428.38% YoY), while the FY2025 annual figure was $770.5 million, up 428.38% from the prior year.
• Common Equity was $770.5 million for Q4 2025 at Belite Bio, up from $145.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $770.5 million in Q4 2025 to a low of -$15.1 million in Q4 2021.
• Historically, Common Equity has averaged $206.6 million across 5 years, with a median of $90.4 million in 2023.
• The sharpest annual moves came in 2021 and 2025: Common Equity plunged 114.48% in 2021, then surged 428.38% in 2025.
• A 5-year view of Common Equity shows it stood at -$15.1 million in 2021, then soared by 374.97% to $41.5 million in 2022, then surged by 117.9% to $90.4 million in 2023, then soared by 61.25% to $145.8 million in 2024, then soared by 428.38% to $770.5 million in 2025.
• The last three Common Equity figures came in at $770.5 million (Q4 2025), $145.8 million (Q4 2024), and $90.4 million (Q4 2023), per Business Quant data.